Sanguine Corporation (OTCBB: SGUI) is pleased to announce that the Company has expanded the use of PHER-O2 by signing a Memorandum of Understanding (MOU) with a medical device company to test the product as a potential carrying agent for a patented MRI procedure. Testing to verify the effective use of PHER-O2 as a carrying agent will be paid for by the medical device company. Management recognizes the importance of this opportunity and believes the worldwide marketplace for an MRI diagnostic carrying agent is substantial.
Dr. Thomas Drees, Sanguine’s CEO, stated, “We are happy to have signed a Memorandum of Understanding (MOU) with this distinguished group. It is a natural step in the process of seeking the commercialization of our PHER-O2 product. The MOU is intended to provide for PHER-O2 testing, which validates the use of PHER-O2 in conjunction with this group’s proprietary diagnostic procedure. Pending PHER-O2’s successful testing, it is Sanguine and the medical device company’s intention to move rapidly into a worldwide product licensing agreement. The agreement will detail a regulatory approval path for this specific application.”
Drees added, “The need for earlier detection of all cancers is essential to the best possible treatment and survival. This is especially true of the most deadly malignancies; cancers of the brain, lung and pancreas, where the mortality rates are significantly higher than other forms. Experts estimate that in the United States there are approximately 275,000 new cases of these three types diagnosed every year; and while this number has declined, the mortality rates from them have risen substantially over the past decade. In fact, the five-year survival rate for patients with Pancreatic cancer, where no screening system exists, is 5% if spread and 20% if localized. The biggest reason is that they are very difficult to detect in their formative stages. The medical community has been searching for a better way to screen for these cancer types and has not been very successful to date. The reason being that detection is often late in the process when pain or other symptoms occur. Should PHER-O2 play a role as a carrier agent for early screening processes, as we believe it very well could, it could lead to a significant achievement in treatment and longevity.”
The device company’s product is in use for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, including, contrast media for medical imaging for use with MRI diagnostic machines, and diagnostic scanning agents in the nature of contrast media for use in “In-Vivo” imaging. As a carrying agent, PHER-O2, in conjunction with the device company’s proprietary diagnostic procedure, could play a significant role in the following:
-- Ability to assess tissue viability in cases of neurological and cardiovascular catastrophes such as (Heart or Stroke attack), or other tissue injury. -- Ability to determine Oxygen Extraction Fraction [OEF] of Tissue such as in stroke at a 1 mm resolution, because they can cross the intact blood brain barrier. [Presently can only be done with PET/CT, using a radio- active isotope oxygen-15] at its best resolution of 6 mm. -- Current PET studies show, with OEF as an indicator the "Golden hour - 3 Hours after onset of Stroke" can now be extended up to 12 hours or more, enabling the clinician and thereby saving lives, reducing disabilities and costs. -- Ability to track tumor angiogenesis. -- Usefulness as "Non Invasive Realtime Tissue Stress Monitor" to evaluate normal and abnormal Oxygen Consumption rates in a biological subject, without any limitations on repeating the test due to dosage and/or other limitations.
For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: [email protected], or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company’s products, increased levels of competition for the Company, new products and technological changes, the Company’s dependence on third-party suppliers, and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.
Contact: For Sanguine Corporation Michael Dancy Investor Relations 801-746-3570 Email Contact
SOURCE: Sanguine Corporation
Comments